International Journal of Clinical Case Reports 2024, Vol.14, No.3, 167-177 http://medscipublisher.com/index.php/ijccr 172 tumor-extrinsic factors like the immunosuppressive tumor microenvironment (Bai et al., 2020). Understanding these mechanisms is crucial for developing strategies to overcome resistance and improve patient outcomes (Elsas et al., 2020; Hanna and Balko, 2021). 4.6 Economic and accessibility issues The high cost of immunotherapy poses significant economic and accessibility challenges. The development and administration of these treatments are expensive, making them inaccessible to many patients, particularly in lowand middle-income countries (Hegde and Chen, 2020). Additionally, the need for specialized infrastructure and trained personnel to administer and monitor immunotherapy further limits its availability. Addressing these economic and accessibility issues is essential to ensure that the benefits of immunotherapy can be extended to a broader patient population (Hegde and Chen, 2020). 5 Future Development Trends in Breast Cancer Immunotherapy 5.1 Emerging therapies and combination treatments 5.1.1 Combination with chemotherapy Combining immunotherapy with traditional chemotherapy has shown promise in enhancing the efficacy of cancer treatments. Chemotherapy can modulate the tumor microenvironment, making it more susceptible to immune attack. For instance, the use of immune checkpoint inhibitors in conjunction with chemotherapy has demonstrated improved outcomes in various cancers, including breast cancer (Khalil et al., 2016; Bou-Dargham et al., 2021). This combination approach aims to leverage the cytotoxic effects of chemotherapy to reduce tumor burden while simultaneously activating the immune system to target residual cancer cells. 5.1.2 Combination with targeted therapies Targeted therapies, such as those inhibiting specific molecular pathways, can be effectively combined with immunotherapy to enhance treatment efficacy. For example, combining PARP inhibitors with immune checkpoint inhibitors has shown potential in treating triple-negative breast cancer (TNBC) (Bou-Dargham et al., 2021). This combination exploits the DNA damage response pathway to increase tumor immunogenicity, thereby enhancing the immune response against cancer cells. Additionally, combining CAR-T cell therapy with small molecule drugs has been explored to overcome the limitations of CAR-T cells in solid tumors (Nguyen et al., 2022). 5.2 Personalized and precision immunotherapy Personalized immunotherapy, tailored to the genetic and molecular profile of individual patients, represents a significant advancement in breast cancer treatment. By utilizing next-generation sequencing and other molecular diagnostic tools, clinicians can identify specific tumor antigens and immune evasion mechanisms unique to each patient. This approach allows for the development of highly specific immunotherapies, such as neoantigen vaccines and personalized CAR-T cells, which can provide more effective and durable responses (Pan et al., 2020). 5.3 Innovations in biomarkers and diagnostic tools The identification and validation of biomarkers are crucial for predicting patient response to immunotherapy and monitoring treatment efficacy. Recent advancements in biomarker discovery have focused on identifying immune-related markers, such as PD-L1 expression and tumor mutational burden, which can guide the selection of appropriate immunotherapeutic agents (Whiteside et al., 2016; Sivaganesh et al., 2021). Additionally, non-invasive diagnostic tools, such as liquid biopsies, are being developed to monitor treatment response and detect early signs of resistance, enabling timely adjustments to therapeutic strategies (Whiteside et al., 2016). 5.4 Advances in CAR-T cell therapy CAR-T cell therapy has revolutionized the treatment of hematological malignancies and is now being explored for solid tumors, including breast cancer. Recent innovations in CAR-T cell engineering, such as the development of "armored" CAR-T cells and dual-targeting CARs, aim to enhance their efficacy and overcome the immunosuppressive tumor microenvironment (Khalil et al., 2016; Nguyen et al., 2022; Schepisi et al., 2023).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==